



AF IAW
1635

Patent Application
Attorney's Docket No.: HYB-015US4

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jiandong Chen, Sudhir Agrawal and Ruiwen Zhang
Application No.: 09/541,848 Group: 1635
Filed: April 3, 2000 Examiner: James Schultz
Confirmation No.: 4238
For: MDM2-SPECIFIC ANTISENSE OLIGONUCLEOTIDES

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Appeal Brief - Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: 10/25/04

Signature

Printed Name: Melanie Legare

APPEAL BRIEF

Mail Stop Appeal Briefs - Patents
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants hereby appeal the Examiner's final rejection of the claims of the above-identified patent application.

Real party in interest

The real party in interest is Hybridon, Inc.

Related appeals and interferences

There are no other appeals or interferences which will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

Status of the claims

Claims 1-13, 17-20, 22, 24, 26, and 28 are pending and are hereby appealed. Claim 16 is pending and allowable. Claims 14-16, 21, 23, 25, 27 and 29 are canceled.

Statement of amendments

No amendments have been made subsequent to final rejection.

Summary of the invention

The invention provides a method for using improved antisense oligonucleotides complementary to a portion of the MDM-2-encoding RNA to inhibit expression of the MDM-2 gene. (page 16, lines 17-18; page 17, lines 7-8). The invention further provides a method for using improved antisense oligonucleotides complementary to a portion of the MDM-2-encoding RNA to inhibit tumor growth *in vivo*. (page 26, lines 5-11; page 29, lines 12-14). The invention also provides methods for using improved antisense oligonucleotides complementary to a portion of the MDM-2-encoding RNA in conjunction with chemotherapeutic agents (page 29, lines 14-16) or radiation (original claim 4). The invention further provides a method for using improved antisense oligonucleotides complementary to a portion of the MDM-2-encoding RNA to increase p53 concentration (page 28, lines 5-7).

Issues

The issue is whether claims 1-13, 17-20, 22, 24, 26, and 28 are enabled by the specification.

Grouping of the claims

The claims appealed stand or fall together.

Argument

Applicants respectfully submit that the presently maintained rejection is in error because the Examiner failed to consider the relevant precedents cited by the Applicants or to apply relevant Patent and Trademark policy. Applicants respectfully submit that one skilled in the art would be taught by the specification how to practice the claimed invention without undue experimentation. The specification accurately teaches how to practice the claimed invention. One skilled in the art could easily reproduce Applicants' results by simply following the examples and the disclosed oligonucleotides. As to other oligonucleotides, undoubtedly some screening using the methods disclosed in the specification and examples would be required. However, these experiments, which would require no modification of the disclosed assays, would not be undue. Such experimentation would be required no matter how many oligonucleotides were exemplified in the specification.

The fact that experimentation may be complex does not necessarily make it undue, if the art typically engages in such experimentation. See M.P.E.P. §2164.01 In the antisense field, scientists typically engage in such screening, and would have to do so no matter how many oligonucleotides are exemplified. In addition, the enablement requirement is met if the description enables any mode of making and using the invention. *Johns Hopkins University v. Cell Pro Inc.*, 152 F.3d 1342, 1360; 47 U.S.P.Q.2d 1705, 1718 (Fed. Cir. 1998), *citing Engel Indus., Inc. v. Lockformer Co.*, 20 U.S.P.Q.2d 1300, 1304 (Fed. Cir. 1991). Applicants have clearly met this requirement.

In *Johns Hopkins University v. Cell Pro Inc.*, the patentee claimed a genus of antibodies which bound to a particular antigen. Cell Pro argued that the specification enabled only a single antibody and that it would require undue experimentation to produce other antibodies within the genus. The Federal Circuit disagreed. It stated that the test for undue experimentation is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention. *Id.*


The present case is exactly analogous. The specification teaches exactly how to proceed to enable the desired generic embodiment of the claims. Only routine experimentation,

following the guidance of the specification, would be required to practice the claimed methods using antisense oligonucleotides and chemotherapeutic agents other than those exemplified in the specification.

Accordingly, the rejection of Claims 1-13, 17-20, 22, 24, 26 and 28 for non-enablement was in error. Applicants therefore request the Board to overturn the rejection and instruct the Examiner to withdraw the rejection and allow the claims.

Respectfully submitted,

Date: 10/25/04

By: 
Wayne A. Keown
Registration No. 33,923

Keown & Associates
500 West Cummings Park
Suite 1200
Woburn, MA 01801
Telephone: 781-938-1805
Facsimile: 781-938-4777

Appendix
Claims involved in the appeal

1. A method of inhibiting expression of MDM2 in a mammal, the method comprising administering to the mammal an effective MDM2-expression inhibiting amount of an anti-MDM2 antisense oligonucleotide, wherein said antisense oligonucleotide comprises from about 8 to about 50 nucleotides that inhibits MDM2 protein expression, said oligonucleotide binding to mdm2-encoding RNA and being complementary to a sequence that overlaps by at least one nucleotide a sequence within the mdm2 RNA, which sequence within the mdm2 RNA is selected from the group consisting of SEQ ID NOS: 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24.
2. The method according to claim 1 comprising co-administering a cancer chemotherapeutic agent.
3. The method according to claim 2, wherein the cancer therapeutic agent is 10-hydroxycamptothecin, adriamycin, or 5-fluorouracil.
4. The method according to claim 1 comprising co-treating the mammal with anti-cancer levels of radiation.
5. A method of inhibiting cancer *in vivo*, the method comprising administering a cancer-inhibiting amount of an anti-MDM2 antisense oligonucleotide, wherein the cancer involves over expression of MDM2, wherein said antisense oligonucleotide

comprises from about 8 to about 50 nucleotides that inhibits MDM2 protein expression, said oligonucleotide binding to mdm2-encoding RNA and being complementary to a sequence that overlaps by at least one nucleotide a sequence within the mdm2 RNA, which sequence within the mdm2 RNA is selected from the group consisting of SEQ ID NOS: 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24.

6. The method according to claim 5, wherein the cancer is selected from the group consisting of osteosarcoma, soft tissue sarcoma, breast cancer, ovarian cancer, cervical cancer, oral squamous cell carcinoma, brain tumor, esophageal cancer, colorectal carcinoma, bladder cancer, urothelial carcinoma, leukemia, and large B cell lymphoma.
7. The method according to claim 5 comprising co-administering an effective cancer-treating amount of a cancer chemotherapeutic agent.
8. The method according to claim 7, wherein the cancer chemotherapeutic agent is 10-hydroxycamptothecin, adriamycin, or 5-fluorouracil.
9. The method according to claim 5 comprising co-treating the mammal with anti-cancer levels of radiation.
10. A method of increasing p53 concentration, the method comprising administering to the cell or to an animal comprising the cell an effective MDM2-expression inhibiting

amount of an anti-MDM2 antisense oligonucleotide, wherein said antisense oligonucleotide comprises from about 8 to about 50 nucleotides that inhibits MDM2 protein expression, said oligonucleotide binding to mdm2-encoding RNA and being complementary to a sequence that overlaps by at least one nucleotide a sequence within the mdm2 RNA, which sequence within the mdm2 RNA is selected from the group consisting of SEQ ID NOS: 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24.

11. The method according to claim 10 comprising co-administering a cancer chemotherapeutic agent.
12. The method according to claim 11, wherein the cancer chemotherapeutic agent is 10-hydroxycamptothecin, adriamycin, or 5-fluorouracil.
13. The method according to claim 10 comprising co-treating the mammal with anti-cancer levels of radiation.
17. The method according to claims 1, 5 or 10, wherein the antisense oligonucleotide has a nucleotide base sequence set forth in Sequence Listing as SEQ ID NO:36.
18. The method according to claims 1, 5 or 10, wherein the antisense oligonucleotide has a nucleotide base sequence set forth in Sequence Listing as SEQ ID NO:27, 28, 29, 30, 31, 32, 33, and 34.

19. The method according to claims 1, 5 or 10, wherein the antisense oligonucleotide has a nucleotide base sequence set forth in Sequence Listing as SEQ ID NO:35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, and 46.
20. The method according to claims 1, 5 or 10, wherein the oligonucleotide has at least one internucleotide linkage selected from the group consisting of phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate, and sulfone internucleotide linkages.
22. The method according to claim 20, wherein the antisense oligonucleotide comprises an RNase H activating segment of four or more consecutive phosphodiester and/or phosphorothioate internucleotide linkages.
24. The method according to claim 22, wherein RNase H activating segment is flanked on both sides by a segment of two or more nucleotides that are modified to increase nuclease resistance and/or target hybridization affinity.
26. The method according to claim 24, wherein the nucleotides of the segments of 2 or more nucleotides are 2'-substituted ribonucleotides.
28. The method according to claim 26, wherein the 2'-substituted nucleotides are substituted at their 2' position with methoxy or methoxyethoxy.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/541,848	
	Filing Date	April 3, 2000	
	First Named Inventor	Chen et al.	
	Art Unit	1635	
	Examiner Name	James Schultz	
Total Number of Pages in This Submission	25	Attorney Docket Number	HYB-015US4

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input checked="" type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks 1. Post Card		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Wayne A. Keown, Ph.D., Reg. No. 33,923
Signature	<i>W. A. Keown</i>
Date	10/25/04

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Appeal Brief - Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Melanie Legare		
Signature	<i>Melanie Legare</i>	Date	10/25/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.